Truist y'day⬆️ $ABCL's PT to $30,⬆️risk adj'd peak sales estimates to $1.1B, reiterated Buy and said -- ABCL635 exceeds our expectations in VMS Ph2, we see best-in-class potential
$BAYRY $ALPMY LLY VERU VTGN
Truist added—ABCL reported Ph2 4-week VMS data that exceeded our expectations.
While we await 12 week data to get a more complete profile, we believe that 4-week results position ABCL635 as clearly differentiated vs. the approved small molecules given its risk-benefit profile and the potentially once monthly injection (vs. daily oral).
We are updating our model to reflect increased confidence in the program. We now estimate peak risk-adjusted sales of $1.1B, up from $641M previously, and raise our price target to $30 per share from $12 per share previously.
$PFE has gained another meaningful oncology catalyst. The FDA granted Priority Review to Talzenna + Xtandi for patients with HRR-mutated metastatic castration-sensitive prostate cancer.
In the Phase 3 trial, the combination reduced the risk of disease progression or death by 52% versus Xtandi alone. An FDA decision is expected in Q4 2026.
This supports Pfizer’s strategy of replacing declining Covid revenue with oncology growth, strengthened by the Seagen acquisition. Astellas Pharma $ALPMY is also worth watching because it is involved with Pfizer in Xtandi.
The next key factors are FDA approval, commercial execution and Pfizer’s upcoming earnings.
Not financial advice. Do your own research.
Cantor reiterated $ABCL Overweight-$11 and said--In 3Q26, ABCL will report Phase 2 data for anti-NK3R antibody ABCL635 in moderate-to-severe vasomotor symptoms (VMS) in menopause, otherwise known as hot flashes.
$BAYRY $ALPMY VTGN LLY
Cantor added—Moderate-to-severe VMS affects >10M women in the U.S. alone every year, symptoms typically last for several years, and the majority of affected women currently don't seek, are averse to, or are explicitly contraindicated for hormonal therapy.
In our view, ABCL635's Phase 2 data will compare favorably to approved NK3R inhibitors (i.e., better impact on VMS severity, similar impact on mean VMS frequency, but better on VMS responder analysis, plus better safety) and ABCL shares will react positively (50%+ upside in ideal scenarios), reflecting the potential multi-$B market opportunity for ABCL635.
$SGMO is heading into Chapter 11 while Eli Lilly ($LLY) and Astellas ($ALPMY) move in as stalking‑horse bidders for key gene therapy platforms and the Fabry program ST‑920.
For $LLY and $ALPMY, this is a chance to lock in enabling gene‑therapy tech at distressed prices. For $SGMO equity, bankruptcy means heavy impairment risk and an uncertain recovery.
Unclaimed Sangamo assets (like neuropathic pain and other programs) could still draw additional bidders, but the main takeaway is clear: partners get the IP, common often gets crumbs.
https://prismmarketview.com/lilly-and-astellas-pick-over-sangamos-gene-therapy-assets-as-biotech-slides-into-bankruptcy/
Barclays🏁 $STRO and said: We initiate coverage of Sutro Bio (STRO) at Overweight with a $56 price target.
$PFE GMAB $ALPMY MRSN MGNX IDYA ABBV
Here's what else Barclays had to say in its initiation report: https://x.com/Quantumup1/status/2059954928584462482?s=20
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase
$ALPMY $BAYRY
Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows
1) target engagement and
2) clean safety profile that could support a superior safety profile vs. competitors.
We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data.
We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses).
We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval:
AbbVie and Genentech: Venclexta (venetoclax)
Astellas Pharma: Xospata (gilteritinib)
Novartis Pharmaceuticals: Rydapt (midostaurin)
Bristol Myers Squibb: Onureg
Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete.
ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study.
SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion +
Mark this post and frame it, Bidding war= $280.00+
🙏✌️❤️🩹
Stifel y'day⬆️ $ABCL's PT to $8 (was $7), reit'd Buy/said it now models ABCL635 peak U.S. sales of $1.4B and $800M in menopause-related VMS and oncology-related (specifically early-stage breast cancer) VMS.
$ALPMY $BAYRY
Here's what Stifel said in its note: https://x.com/Quantumup1/status/2054180048857424221?s=20
Cantor reiterated $ANNX Overweight
ISEE - $ALPMY
BofA reit'd Buy; $8 after ANNX's Geographic Atrophy Investor Day where BofA said: Vonaprument's novel MoA could drive visual acuity benefit
Here's what Cantor and BofA had to say: https://x.com/Quantumup1/status/2034658656029954490?s=20
Vir Biotechnology (NASDAQ: VIR) Soars 27.7% on Big Pharma Deal: https://www.smartinvestornews.com/all-articles/vir-biotechnology-nasdaq-vir-soars-27-7-on-big-pharma-deal $VIR $ALPMY
$VIR: Vir Biotechnology (+34.5%) surging on earnings and updated Phase 1 trial results for PSMA-targeting, PRO-XTEN dual-masked T-cell engager VIR-5500. Also strategic collaboration with Astelas Pharma $ALPMY; and upgraded to Strong Buy from Outperform at Raymond James.
$SGMO $SGMO $ALPMY The Astellas presentation at JPM Healthcare conference is at 3p PT today. Hopefully we at least get some strong hints that tilt us toward Astellas, or perhaps Takeda. Supposedly, a copy of the presentation materials and webcast link will be posted on the http://Astellas.com investor relations page later today, but I haven’t seen anything yet. Very interesting that they’re doing a webcast!
ASCO GI 2026: What to watch
The data is LIVE and Alpha Tau is the standout. Two massive abstracts prove Alpha DaRT is the next frontier in internal oncology:
$DRTS - Abstract #1 shows breakthrough safety in advanced Pancreas cancer treatment. Ultra-high dose precision in "inoperable" tumors. Abstract #2 highlights immune markers-turning the tumor into its own vaccine. 31% insider skin-in-the-game + $12 analyst PT.
$ACTU - Jan 9 Oral session on Elraglusib. Risk of death reduced by 37% in early looks. The market wants the full survival curves.
$RNXT - Abstract #732. Proving their TAMP platform hits the tumor harder with fewer side effects than systemic chemo.
$ALPMY - Late-breaking data on Zolbetuximab. Setting the "Precision" ceiling for the Gl sector
